Human health and animal health are inextricably linked. Merck is committed to both.
Merck Animal Health, one of Merck's fastest growing business areas, is dedicated to preserving and improving the health, well-being and performance of both companion and farm animals—which is good not only for animals but also good for humans.
According to the World Health Organization, about 75 percent of the new diseases that have affected humans over the past 10 years have been caused by pathogens originating from an animal or from products of animal origin.
The emergence of these novel pathogenic disease strains is likely to have been accelerated by the interdependency between humans, animals and the environment due to increases in:
DEMAND FOR ANIMAL PROTEIN AS A FOOD SOURCE
Annual meat production is expected to increase from 218 million tons in 1997-1999 to 376 million tons by 2030
INTERNATIONAL TRADE IN LIVE ANIMALS AND FOOD PRODUCTS
79.7 million U.S. households reported owning pets in 2015, up from 66.5 million in 2011
“Strengthening the knowledge exchange between animal health and human health researchers to identify opportunities to prevent disease transmission is more important now than ever,”said Richard R. DeLuca, Jr., president, Merck Animal Health.“Improving animal health may help to improve human health.”
Richard R. DeLuca, Jr., president, Merck Animal Health
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA
This website of Merck & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
No Duty to Update
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.